The Centers for Medicare & Medicaid Services (CMS) has announced a new initiative called the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model. This model outlines how the administration plans to explore expanding access to obesity care with certain GLP-1 medications for people enrolled in Medicare and Medicaid. The model will also
Read Article

A Lifetime of Struggle Shekinah Samaya-Thomas has lived with chronic obesity since she was 18 months old. For most of her life, she was trapped in a relentless cycle of weight loss and regain, declining health and delayed or denied access to supportive healthcare. Name a weight reduction program—she did it. Countless pounds came off,
Read Article

Tampa, FL., December 1, 2025 – Statement from Obesity Action Coalition (OAC) President and CEO Joe Nadglowski: “The World Health Organization’s new recommendation for GLP-1 medications as part of a long-term treatment strategy for obesity is a significant milestone in recognizing obesity as a chronic, treatable disease. These medications, which can help reduce weight and
Read Article

When my A1C hit 10.2, I knew I was in dangerous territory. Type 2 diabetes had taken hold, and the future looked terrifying. Then I started a GLP-1 medication. Within months, my A1C dropped into the 6s. My health stabilized. For the first time in years, I felt like I had control over my body
Read Article

Managing your weight and health is a journey, and we understand how frustrating it can be when promising treatments like Wegovy (semaglutide) or Zepbound (tirzepatide) are out of reach. With shortages and high costs, it’s tempting to consider other options, like compounded GLP-1 medications. But here’s why that’s a risky path you should avoid.  The
Read Article

The anti-obesity medication Wegovy® has been approved by the US Food and Drug Administration (FDA) for cardiovascular risk reduction in people with overweight or obesity and an established cardiovascular disease. The approval is based on the SELECT cardiovascular outcomes trial, which demonstrated that Wegovy® statistically significantly reduced the risk of major adverse cardiovascular events. Obesity
Read Article